Rights and permissions
About this article
Cite this article
Celecoxib most cost-effective choice in high-risk arthritis patients. Pharmacoecon. Outcomes News 474, 12 (2005). https://doi.org/10.2165/00151234-200504740-00025
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200504740-00025